CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme

Cardiovascular Drug Reviews

Volumn 23, Issue 4, 2005, Pages 317-330

  Battistini, Bruno ^a,b,d   Daull, Philippe ^a   Jeng, Arco Y ^c,d  

^a LAVAL UNIVERSITY   (Canada)

^b IPS Pharma Inc   (Canada)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

Angiotensin; Angiotensin converting enzyme; CGS 35601; CGS 37808; Endothelin; Endothelin converting enzyme; Neutral endopeptidase

Indexed keywords

2 (4 BIPHENYLYL) 1 (1H TETRAZOL 5 YL)ETHYLAMINOMETHYLPHOSPHONIC ACID; ADRENOMEDULLIN; ANGIOTENSIN I; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR ALPHA; AVE 7688; BENAZEPRIL; BIG ENDOTHELIN 1; BIOLOGICAL MARKER; BRADYKININ; CGS 24592; CGS 35601; CGS 37808; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENKEPHALINASE INHIBITOR; GW 796406; MEMBRANE METALLOENDOPEPTIDASE; N [2 (MERCAPTOMETHYL) 3 METHYLBUTANOYL] 4 (1H PYRAZOL 1 YL) 1 PHENYLALANINE; N [2 (PHOSPHONOMETHYL)AMINO 3 (4 BIPHENYL)PROPIONYL] 3 AMINOPROPIONIC ACID; N [[1 [(2 MERCAPTO 4 METHYL 1 OXOPENTYL)AMINO]CYCLOPENTYL]CARBONYL]TRYPTOPHAN; N [[1 [[2 (ACETYLTHIO) 4 METHYL 1 OXOPENTYL]AMINO]CYCLOPENTYL]CARBONY]TRYPTOPHAN METHYL ESTER; NATRIURETIC FACTOR; NITRIC OXIDE; OMAPATRILAT; PHENYLALANINE DERIVATIVE; PRODRUG; PROPIONIC ACID DERIVATIVE; TRYPTOPHAN DERIVATIVE; UNCLASSIFIED DRUG; VASOPEPTIDASE INHIBITOR;

ANTIHYPERTENSIVE ACTIVITY; BLOOD VESSEL TONE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; EXPERIMENTAL MODEL; HUMAN; HYPERTENSION; IC 50; MEDIATOR RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 33744957126     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2005.tb00175.x     Document Type: Review

References (51)

1. Adam A, Cugno M, Molinaro G, Perez M, Lepage Y, Agostoni A. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 2002;359:2088-2089.
2. American Heart Association. Heart Disease and Stroke Statistics. Dallas: American Heart Association, 2005.
3. Battistini B, Ayach B, Molez S, Blouin A, Jeng AY. Effects of benazepril, an angiotensin-converting enzyme inhibitor, combined with CGS 35066, a selective endothelin-converting enzyme inhibitor, on arterial blood pressure in normotensive and spontaneously hypertensive rats. Clin Sci (Lond) 2002;103:S363-S366.
4. Battistini B, Jeng AY. Therapeutic promises of endothelin receptor antagonists and endothelin converting enzyme inhibitors. Pharm News 1999;6:15-20.
5. Blais C Jr, Marceau F, Rouleau JL, Adam A. The kallikrein-kininogen-kinin system: Lessons from the quantification of endogenous kinins. Peptides 2000;21:1903-1940.
6. Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. J Allergy Clin Immunol 2004;114:629-637.
7. Bruno CM, Meli S, Marcinno M, Ierna D, Sciacca C, Neri SJ. Plasma endothelin-1 levels and albumin excretion rate in normotensive, microalbuminuric type 2 diabetic patients. Biol Regul Homeost Agents 2002; 16:114-117.
8. Burnett JC Jr. Vasopeptidase inhibition: A new concept in blood pressure management. J Hypertens 1999; 17(Suppl 1):S37-S43.
9. Calixto JB, Medeiros R, Fernandes ES, Ferreira J, Cabrini DA, Campos MM. Kinin B1 receptors: Key G-protein-coupled receptors and their role in inflammatory and painful processes. Br J Pharmacol 2004;143: 803-818.
10. Ciafre SA, D'Armiento FP, Di Gregorio F, et al. Angiotensin II stimulates endothelin-1 release from human endothelial cells. Recent Prog Med 1993;84:248-253.
11. Corti R, Burnett JC Jr, Rouleau JL, Ruschitzka F, Luscher TF. Vasopeptidase inhibitors: A new therapeutic concept in cardiovascular disease? Circulation 2001;104:1856-1862.
12. Daull P, Benrezzak O, Arsenault D, et al. Triple Vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained and spontaneously hypertensive rats. Am J Hypertens 2005;18:1606-1613.
13. Daull P, Blouin A, Beaudoin M, et al. CGS 35601, a single molecule triple Vasopeptidase inhibitor, modulates the hemodynamic and metabolic profiles in chronically instrumented, conscious and unrestrained type II Zucker diabetic fatty rats. Exp Biol Med 2006; In press.
14. Daull P, Blouin A, Belleville K, et al. CGS 35601, a triple Vasopeptidase inhibitor, reduces hypertension in instrumented Dahl salt-sensitive rats fed a high-salt diet. Exp Biol Med 2006; In press.
15. Daull P, Lepage R, Benrezzak O, et al. The first pre-clinical pharmacotoxicological safety assessment of CGS 35601, a triple Vasopeptidase inhibitor, in chronically instrumented, conscious and unrestrained spontaneously hypertensive rats. Drug Chem Toxicol 2006;29(2): In press.
16. Duan QL, Nikpoor B, Dube MP, et al. A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am J Hum Genet 2005;77:617-626.
17. Dzau VJ, Bernstein K, Celermajer D, et al. The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data. Am J Cardiol 2001;88(Suppl 9A):1L-20L.
18. Emanueli C, Chao J, Regoli D, Chao L, Ni A, Madeddu P. The bradykinin B1 receptor and the central regulation of blood pressure in spontaneously hypertensive rats. Br J Pharmacol 1999;126:1769-1776.
19. Eto T. A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides. Peptides 2001;22:1693-1711.
20. Fink CA, Moskal M, Firooznia F, et al. Design and synthesis of potent thiol-based inhibitors of endothelin converting enzyme-1. Bioorg Med Chem Lett 2000;10:2037-2039.
21. Gross O, Koepke ML, Beirowski B, Schulze-Lohoff E, Segerer S, Weber M. Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688. Kidney Int 2005;68:456-463.
22. Hayakawa H, Coffee K, Raij L. Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: Effects of antihypertensive therapy. Circulation 1997;96:2407-2413.
23. Inguimbert N, Poras H, Dhotel H, et al. In vivo properties of thiol inhibitors of the three vasopeptidases NEP, ACE and ECE are improved by introduction of a 7-azatryptophan in P2′ position. J Pept Res 2004;63: 99-107.
24. Kostis JB, Cobbe S, Johnston C, et al. Design of the omapatrilat in persons with enhanced risk of atherosclerotic events (OPERA) trial. Am J Hypertension 2002;15:193-198.
25. Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) Trial. Am J Hypertension 2004;17(2):103-111.
26. Ksander GM, Savage P, Trapani AJ, Balwierczak JL, Jeng AY. Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme. J Cardiovasc Pharmacol 1998;31:S71-S73.
27. Kukkola PJ, Savage P, Sakane Y, et al. Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: Endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme. J Cardiovasc Pharmacol 1995;26:S65-S68.
28. Lawson SR, Gabra BH, Nantel F, Battistini B, Sirois P. Effects of a selective bradykinin Bl receptor antagonist on increased plasma extravasation in streptozotocin-induced diabetic rats: Distinct vasculopathic profile of major key organs. Eur J Pharmacol 2005;514:69-78.
29. Liesmaa I, Kuoppala A, Shiota N, et al. Increased expression of bradykinin type-1 receptors in endothelium of intramyocardial coronary vessels in human failing hearts. Am J Physiol Heart Circ Physiol 2005;288: H2317-H2322.
30. Maki T, Nasa Y, Tanonaka K, Takahashi M, Takeo S. Direct inhibition of neutral endopeptidase in vasopeptidase inhibitor-mediated amelioration of cardiac remodeling in rats with chronic heart failure. Mol Cell Biochem 2003;254:265-273.
31. McClean DR, Ikram H, Garlick AH, Richards AM, Nicholls MG, Crozier IG. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol 2000;36:479-486.
32. McDowell G, Coutie W, Shaw C, Buchanan KD, Struthers AD, Nicholls DP. The effect of the neutral endo-peptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol 1997;43:329-332.
33. McKittrick BA, Stamford AW, Weng X, et al. Design and synthesis of phosphonic acids that triply inhibit endothelin converting enzyme, angiotensin converting enzyme and neutral endopeptidase 24.11. Bioorg Med Chem Lett 1996;6:1629-1634.
34. Mellin V, Jeng AY, Monteil C, et al. Triple ACE-ECE-NEP inhibition in heart failure: A comparison with ACE and dual ECE-NEP inhibition. J Cardiovasc Pharmacol 2005;46:390-397.
35. Molinaro G, Cugno M, Perez M, et al. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. J Pharmacol Exp Ther 2002;303: 232-237.
36. B receptor in kidneys of mice with unilateral obstruction. Am J Physiol Renal Physiol 2003;284:F209-F217.
37. Pu Q, Amiri F, Gannon P, Schiffrin EL. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats. J Hypertens 2005;23: 401-409.
38. Richards AM, Wittert GA, Crozier IG, et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: Evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993;11:407-416.
39. Roques BP. Novel approaches to targeting neuropeptide systems. Trends Pharmacol Sci 2000;21:475-483.
40. Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356:615-620.
41. Schafer S, Linz W, Vollert H, et al. The vasopeptidase inhibitor AVE7688 ameliorates type 2 diabetic nephropathy. Diabetologia 2004;47:98-103.
42. Stasch JP, Knorr A, Hirth-Dietrich C, et al. Long-term blockade of the angiotensin II receptor in renin transgenic rats, salt-loaded Dahl rats, and stroke-prone spontaneously hypertensive rats. Arzneimittelforschung 1997;47:1016-1023.
43. Sugimoto K, Gotoh E, Takasaki I, et al. AT1 receptor antagonist, TCV 116, does not prevent cardiac hypertrophy in salt-loaded Dahl salt-sensitive rats. Clin Exp Pharmacol Physiol 1996;23:282-286.
44. Sulpizio A, Pullen MA, Edwards RM, Louttit JB, West RI, Brooks DP. Mechanism of vasopeptidase inhibitor-induced plasma extravasation: Comparison of omapatrilat and the novel neutral endopeptidase 24.11 angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther 2005;315:1306-1313.
45. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 1990;33:306-310.
46. Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 1998;11:363-372.
47. Trapani AJ, Beil ME, Bruseo CW, Savage P, Firooznia F, Jeng AY. CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme. J Cardiovasc Pharmacol 2004;44:S211-S215.
48. Wassef L, Langham RG, Kelly DJ. Vasoactive renal factors and the progression of diabetic nephropathy. Curr Pharm Des 2004;10:3373-3384.
49. Xu J, Carretero OA, Liu YH, et al. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure. J Card Fail 2004;10:83-89.
50. Yusuf S, Loon E, Bosch J, Gerstein H. Summary of randomized trials of angiotensin converting enzyme inhibitors. Clin Exp Hypertens 1999;21:835-845.
51. Zanchi A, Maillard M, Burnier M. Recent clinical trials with omapatrilat: New developments. Curr Hypertens Rep 2003;5:346-352.